Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laine Marrah

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|December 24, 2021
Targeting AVIL, a New Cytoskeleton Regulator in GlioblastomaRobert Cornelison, Laine Marrah, Drew Horter, et al.
NAR Genomics and Bioinformatics|June 6, 2022
tRForest: a novel random forest-based algorithm for tRNA-derived fragment target predictionRohan Parikh, Briana Wilson, Laine Marrah, et al.
International Journal of Molecular Sciences|September 28, 2023
The Potential for Targeting AVIL and Other Actin-Binding Proteins in RhabdomyosarcomaRobert Cornelison, Laine Marrah, Adelaide Fierti, et al.
Science Translational Medicine|January 28, 2026
A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastomaZhongqiu Xie, Pawel Ł Janczyk, Robert Cornelison, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|December 24, 2021
Targeting AVIL, a New Cytoskeleton Regulator in GlioblastomaRobert Cornelison, Laine Marrah, Drew Horter, et al.
NAR Genomics and Bioinformatics|June 6, 2022
tRForest: a novel random forest-based algorithm for tRNA-derived fragment target predictionRohan Parikh, Briana Wilson, Laine Marrah, et al.
International Journal of Molecular Sciences|September 28, 2023
The Potential for Targeting AVIL and Other Actin-Binding Proteins in RhabdomyosarcomaRobert Cornelison, Laine Marrah, Adelaide Fierti, et al.
Science Translational Medicine|January 28, 2026
A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastomaZhongqiu Xie, Pawel Ł Janczyk, Robert Cornelison, et al.
Pageof 1